SARS-CoV-2 and blood-borne viral coinfections are well reported. Nevertheless, little is known regarding the seroprevalence of SARS-CoV-2 and coinfection with blood-borne viruses in hematologic malignancy patients in Ethiopia. We aimed to assess the seroprevalence of SARS-CoV-2 and associated infections with hepatitis B and other viruses among adolescent and adult acute leukemia patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. A cross-sectional study was conducted from July 2020 to June 2021. Blood samples were tested for the presence of anti-SARS-CoV-2, HBV, HCV, and HIV with ELISA kits and occult hepatitis B infection with a real-time polymerase chain reaction assay. Out of a total 110 cases, the SARS-CoV-2 seroprevalence was 35.5%. The prevalence showed a significant increment from July 2020 to the end of June 2021 (p= 0.015). In 22.7% and 2.7% of leukemia cases, HBV and HIV, respectively, were detected. No HCV was identified. The rate of SARS-CoV-2 coinfection with HBV and HIV was 28% (11/39) and 2.6% (1/39), respectively; however, there was no statistically significant association between SARS-CoV-2 seropositivity with HBV and HIV (p> 0.05). There is a need for viral screening in leukemia cases to monitor infections and inform management.
SARS-CoV-2与血源性病毒合并感染的病例已有充分报道。然而，关于埃塞俄比亚血液系统恶性肿瘤患者中SARS-CoV-2的血清阳性率及其与血源性病毒合并感染的情况，目前知之甚少。本研究旨在评估埃塞俄比亚亚的斯亚贝巴提库尔安贝萨专科医院青少年及成人急性白血病患者中SARS-CoV-2的血清阳性率及其与乙型肝炎等病毒的合并感染情况。研究于2020年7月至2021年6月开展横断面调查，采用ELISA试剂盒检测血液样本中抗SARS-CoV-2抗体、HBV、HCV及HIV，并运用实时聚合酶链反应检测隐匿性乙型肝炎感染。在110例病例中，SARS-CoV-2血清阳性率为35.5%，且从2020年7月至2021年6月末呈显著上升趋势（p=0.015）。白血病病例中HBV和HIV检出率分别为22.7%和2.7%，未检出HCV。SARS-CoV-2与HBV、HIV的合并感染率分别为28%（11/39）和2.6%（1/39），但SARS-CoV-2血清阳性与HBV、HIV感染无统计学显著关联（p>0.05）。建议对白血病病例开展病毒筛查以监测感染情况并指导临床管理。
Seroprevalence of SARS-CoV-2 and Hepatitis B Virus Coinfections among Ethiopians with Acute Leukemia
肿瘤(癌症)患者之家